Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Norway has seen a steady growth in recent years, driven by various factors such as customer preferences, local special circumstances and underlying macroeconomic factors.
Customer preferences: Norwegian customers have shown a growing demand for immunosuppressants due to the increasing prevalence of autoimmune diseases and organ transplant procedures. Additionally, the rising geriatric population and the subsequent increase in chronic diseases have led to a greater need for immunosuppressants.
Trends in the market: The market for immunosuppressants in Norway is expected to grow due to the increasing demand for these drugs. The market is also expected to see a shift towards the use of biologic drugs, which offer better efficacy and fewer side effects than traditional small molecule drugs. Furthermore, the market is expected to see an increase in the use of biosimilars due to their lower cost compared to biologics.
Local special circumstances: Norway has a universal healthcare system which provides access to immunosuppressants to all citizens, regardless of their ability to pay. The Norwegian government has also taken measures to promote the use of biosimilars in order to reduce healthcare costs. These factors have contributed to the growth of the immunosuppressants market in Norway.
Underlying macroeconomic factors: The Norwegian economy has been growing steadily over the past few years, which has led to an increase in healthcare spending. Additionally, the Norwegian government has made investments in healthcare infrastructure, which has led to an increase in the availability of immunosuppressants. These underlying macroeconomic factors have contributed to the growth of the immunosuppressants market in Norway.In conclusion, the immunosuppressants market in Norway is expected to continue to grow due to the increasing demand for these drugs, the shift towards the use of biologic drugs and biosimilars, the universal healthcare system, and the underlying macroeconomic factors.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
